 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. NASDAQ:HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumabTM, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19. The Company expects to announce top-line data in March 2021. The primary objective of this Phase 3 randomized, double-blind, placebo-controlled clin 